Intellectual Property Industries

BiologicsHQ

Information contained in the BiologicsHQ database relates to FDA-approved drug products listed in the CDER Purple Book
Read More

Identical Marks, Identical Types of Products: Not Enough to Presume Confusion

October 15, 2020

1min

In the Age of Digital Interconnectivity

May 06, 2020

1min

Gaming Emote Litigation: Battle Royale Ensues Over Fortnite Emotes with Plaintiffs Testing Different Causes of Action

April 21, 2020

8min

Biosimilars Contested Proceedings, Litigation and Patent Law

January 22 - 24, 2020 Informa’s Specialty Therapies and Biosimilars Congress

The Top Copyright Issues Facing Nonprofits

September 17, 2019 Washington, DC - A Complimentary Venable LLP Seminar/Webcast

Patent Trial and Appeal Board Denies Institution of Inter Partes Review of Novartis’s Entresto® Patent on Combination of Valsartan and Sacubitril

February 16, 2021

1min

Westlaw Journal Intellectual Property Features Q&A with Meaghan Kent on the CASE Act

January 26, 2021

1min

Center for Biosimilars Quotes Ha Kung Wong on Insulin Product’s Progress Along 351(k) Biologics License Application Pathway

June 15, 2020

2min